Literature DB >> 22031337

Combined normal donor and CLL: Single tube ZAP-70 analysis.

Heba A Degheidy1, David J Venzon, Mohammed Z H Farooqui, Fatima Abbasi, Diane C Arthur, Wyndham H Wilson, Adrian Wiestner, M A Stetler-Stevenson, Gerald E Marti.   

Abstract

INTRODUCTION: Zeta-chain-associated protein kinase 70 (ZAP-70) has been identified as an independent prognostic marker in chronic lymphocytic leukemia (CLL). Based on our previous studies, we have developed a combined one-tube technology with multiple internal controls to optimize ZAP-70 assessment.
METHODS: Forty-eight untreated CLL cases were examined for ZAP-70 expression using a modified 7-color one-tube assay. Normal donor (ND) whole blood is stained with CD3 APC-Cy7 and CD19 APC. In a second tube, patient whole blood is stained with CD5 PE-Cy7, CD19 PerCP-Cy5.5, and CD20 eFluor450. After surface staining and fixation, these two tubes are combined. After saponin permeabilization, the cells were stained with two anti-ZAP-70 clones (1E7.2/AF488 and SBZAP/PE). The results obtained from this modified tube were compared with those obtained concurrently using the non-mixed single sample tubes. Five different methods of ZAP-70 expression analysis were evaluated: percentage positive cells using ND T-cells as a reference; the internal patient T-cell/clone ratio; ND T-cell/clone ratio; clone/ND B-cell ratio; and modified Z-index. RESULT: Overall, the combined patient and ND mix tube performed better than the non-mixed single sample tube. The strongest correlations between ZAP-70 expression and immunoglobulin heavy chain variable (IGHV) mutational status were seen with percentage positive ND T-cell, ND T-cell/clone ratio, and clone/ND B-cell ratio for both 1E7.2 and SBZAP clone (P < 0.0001).
CONCLUSION: The modified one tube method combining the ND and patient sample provides highly reliable results that correlate with the IGHV mutational status. This method should be considered as part of the next step in standardization of the ZAP-70 assay in CLL. Published 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031337      PMCID: PMC3407416          DOI: 10.1002/cyto.b.20622

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  21 in total

1.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

2.  An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia.

Authors:  T Vincent Shankey; Meryl Forman; Paul Scibelli; Jeffrey Cobb; Cecilia M Smith; Rhonda Mills; Karen Holdaway; Elizabeth Bernal-Hoyos; Mafalda Van Der Heiden; Jan Popma; Mike Keeney
Journal:  Cytometry B Clin Cytom       Date:  2006-07-15       Impact factor: 3.058

Review 3.  Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Thomas J Kipps
Journal:  Cytometry B Clin Cytom       Date:  2006-07-15       Impact factor: 3.058

4.  Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.

Authors:  Nathalie Gachard; Aurélie Salviat; Catherine Boutet; Christine Arnoulet; Françoise Durrieu; Bernard Lenormand; Stéphane Leprêtre; Sylviane Olschwang; Fabrice Jardin; Marina Lafage-Pochitaloff; Dominique Penther; Danielle Sainty; Liliane Reminieras; Jean Feuillard; Marie C Béné
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

5.  A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).

Authors:  Antony C Bakke; Zoe Purtzer; Jose Leis; James Huang
Journal:  Cytometry B Clin Cytom       Date:  2006-07-15       Impact factor: 3.058

6.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

Review 7.  Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.

Authors:  Marco Montillo; Terry Hamblin; Michael Hallek; Emili Montserrat; Enrica Morra
Journal:  Haematologica       Date:  2005-03       Impact factor: 9.941

8.  Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Authors:  Francesca M Rossi; Maria Ilaria Del Principe; Davide Rossi; Maria Irno Consalvo; Fabrizio Luciano; Antonella Zucchetto; Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Marco Fangazio; Dania Benedetti; Massimo Degan; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2010-03-08       Impact factor: 5.531

9.  Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

Authors:  Andreas Rosenwald; Eric Y Chuang; R Eric Davis; Adrian Wiestner; Ash A Alizadeh; Diane C Arthur; James B Mitchell; Gerald E Marti; Daniel H Fowler; Wyndham H Wilson; Louis M Staudt
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

10.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.